- GLP-1 (7-37)
-
- $80.00 / 1kg
-
2024-05-10
- CAS:106612-94-6
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
- GLP-1 (7-37)
-
- $28.00 / 1box
-
2024-05-10
- CAS:106612-94-6
- Min. Order: 1box
- Purity: 99%
- Supply Ability: 20000
- GLP-1 (7-37)
-
- $10.00 / 1kg
-
2024-03-08
- CAS:106612-94-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
|
| | GLP-1 (7-37) Basic information |
| Product Name: | GLP-1 (7-37) | | Synonyms: | Insulinotropin (human);Peptide GLP-1 (human glucose-lowering peptide-1);Glp-I (7-37);Glucagon like peptide I (7-37);Glucagon-related peptide (oncorhynchus kisutch), 3-L-glutamic acid-6-L-phenylalanine-9-L-aspartic acid-12-L-serine-15-L-glutamic acid-16-glycine-21-L-isoleucine-24-L-alanine-27-L-valine-28-L-lysine-31-glycine-;Tglp-1;GLP-1, 7-37;Preproglucagon 78-108 | | CAS: | 106612-94-6 | | MF: | C151H228N40O47 | | MW: | 3355.67 | | EINECS: | | | Product Categories: | peptides pharm;peptide | | Mol File: | 106612-94-6.mol |  |
| | GLP-1 (7-37) Chemical Properties |
| density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | Water:30.0(Max Conc. mg/mL);8.34(Max Conc. mM) | | form | Lyophilized powder | | Water Solubility | Soluble in water at 2mg/ml | | Sequence | H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH | | CAS DataBase Reference | 106612-94-6 |
| | GLP-1 (7-37) Usage And Synthesis |
| Description | GLP-1 (7-37) is an endogenous truncated form of GLP-1 that arises from proglucagon processing in intestinal endocrine L cells, GLP-1 (7-37) acts as a GLP-1 receptor agonist and is an insulinotropic hormone that augments glucose induced insulin secretion. GLP-1 (7-37) and derivatives GLP-1 (9-37) and GLP-1 (28-37) can reduce plaque inflammation and increase phenotypic characteristics of plaque stability in a murine model of atherosclerosis. | | Uses | Glucagon-Like Peptide 1 Fragment 7-37 human has been used:
- as a positive control for insulin secretion of pancreatic islets
- to test its effect on insulin response in horse islets
- in combination with mesenchymal stem cells (MSCs) test its protective effects in myocardial infarction
| | General Description | Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) is an amino-truncated form of GLP-1. | | Biochem/physiol Actions | Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) interacts with the GLP-1 receptor (GLP-1r). It mediates insulin release by stimulating the cyclic AMP accumulation in islet cells GLP-l(7-37) is a potential therapeutic agent due to its insulin-secretagogue functionality. | | in vitro | In vitro, truncated glucagon-like peptides [GLP-1(7-36)-amide and GLP-1(7-37)] increase insulin secretion in a glucose-dependent manner, and desensitization to the action of GLP-1(7-37) has been demonstrated acutely with high concentrations. | | in vivo | GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats.
Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM. | | storage | Store at -20°C |
| | GLP-1 (7-37) Preparation Products And Raw materials |
|